JAK1 and non-small cell lung carcinoma: Recent studies have also shown that EPN3 plays an oncogenic role in NSCLC by activating the JAK1/2-STAT3 pathway and that inhibiting EPN3 can reduce the metastasis and invasion ability of LUAD cells by inhibiting the EMT process [34, 35].